LBPH

Investor Moves

Name	Value	Action	Change	Price	Current Price
Andreas HalvorsenViking Global $-65.6M ExitQ4 2024 $66M -- $59.98
Ken GriffinCitadel Advisors $-873.2K ExitQ4 2024 $873k -- $59.98
Paul Tudor Jones IITudor Investment $-630.8K ExitQ4 2024 $631k -- $59.98
Steven CohenPoint72 $-27.9M ExitQ3 2024 $28M -- $59.98
Andreas HalvorsenViking Global $20.8M AddQ3 2024 $21M -- $59.98
Ken GriffinCitadel Advisors $343.5K AddQ3 2024 $343k -- $59.98

Insider Trades

Name	Value	Action	Price	Current Price
Kaye RandallCMO $984k16.7k shares SellOct 15, 2024 $59.04 $59.98
Kaye RandallCMO $289k9.4k shares SellSep 16, 2024 $30.89 $59.98
Kaye RandallCMO $134k4.2k shares SellSep 16, 2024 $31.81 $59.98
Kaye RandallCMO $65k1.9k shares SellSep 16, 2024 $34.04 $59.98
Kaye RandallCMO $40k1.2k shares SellSep 16, 2024 $33.12 $59.98
Kaye RandallCMO $362k10.5k shares SellAug 12, 2024 $34.55 $59.98

Trade LBPH

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.

CEO: Kevin R. Lind
IPO Date: Mar 12, 2021

Market Data

High: $59.98
Low: $59.98
Volume: 0
52W High: $59.98
52W Low: $59.98

Valuation

Market Cap: $2.3B
Enterprise Value: $2.3B

Financials

Free Cash Flow: -$50.9M
Revenue: $0
Net Income: -$54.4M
Cash: $14.3M
Debt: $475K

Events

EarningsNov 7

EPS est. -0.59 · actual -0.63